From the 2022 Joint Annual
Meeting (recorded 6/27/2022)
Presented by Brandy
Gunsolus, DCLS, MLS(ASCP)CM
Primary Aldosteronism (PA)
accounts for nearly 10 percent of all hypertensive patients, but only 3 percent
of hypertensive patients are tested for it. This session will discuss the renin–angiotensin–aldosterone
system (RAAS), testing for PA, and direct renin concentration vs plasma renin
activity. AVS testing performed during confirmatory and treatment procedures
will also be discussed.
LEARNING OBJECTIVES
At the conclusion of this presentation,
participants will be able to:
- Identify components of the renin-angiotensin-aldosterone system (RAAS) and its implication on hypertension.
- Describe and understand key difference between plasma renin activity (PRA) and direct renin concentration (DRC) assays.
- Discuss proposed age-specific plasma aldosterone/plasma renin ratio (ARR) cutoffs for primary aldosteronism screening.
CE ACCREDITATION
ASCLS is approved as a provider of continuing
education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ®
Program. One (1) P.A.C.E. ® contact hour and one (1) Florida credit hour in the
area of Chemistry (Chemistry) will be
awarded to participants. ASCLS P.A.C.E.® is accepted by the ASCP/ASCLS/AGT
Board of Certification and all states, including Florida and California, as an
approved provider of continuing education for recertification and licensure.
ASCLS is an approved provider with CE Broker for Florida licensees.
LEVEL OF INSTRUCTION
This Intermediate-level
program is appropriate for laboratory professionals working in clinical, public
health and academic settings.